<DOC>
	<DOCNO>NCT00972179</DOCNO>
	<brief_summary>This study follow randomize , multiple-dose , double-blind , placebo-controlled , sequential dose-escalation study design . This healthy volunteer study consist five subcutaneous ( SC ) cohorts one intravenous ( IV ) cohort . Each dose cohort enroll 8 subject , randomize 6 subject receive AMG 157 2 receive placebo ( 3:1 ratio ) . The dos AMG 157 plan evaluate include 35 mg ( SC every 28 day , Cohort 1 ) , 105 mg ( SC every 28 day , Cohort 2 ) , 210 mg ( SC every 28 day , Cohort 3 ) , 210 mg ( SC every 14 day , Cohort 4 ) , 210 mg ( SC every 7 day , Cohort 5 ) 700 mg ( IV every 28 day , Cohort 6 ) .</brief_summary>
	<brief_title>Safety Study AMG 157 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects must sign Institutional Review Board ( IRB ) approve informed consent form studyspecific procedure ; Healthy subject , age 18 45 year , inclusive ; Female subject must nonreproductive potential ( ie , postmenopausal history menses ≥ 1 year FSH [ use local reference range ] ; OR history hysterectomy ; OR history bilateral tubal ligation ; OR history bilateral oophorectomy ) ; Male subject female partner childbearing potential agrees inform female partner participation clinical study use highly effective method birth control study . ( Highly effective method birth control may include abstinence , vasectomy , condom spermicide combination either hormonal birth control , IUD barrier method use woman . ) ; Male subject agree use birth control five month last dose study medication , male subject agree donate sperm study five month last dose study medication ; Healthy subject body mass index ( BMI ) 18 32 kg/m2 , inclusive screening ; Subject must normal clinically acceptable physical examination electrocardiogram ( ECG ) result ( 12lead reporting RR , PR , QRS , QT QTcF ) prior Day 1 base opinion investigator ; Subject must normal clinically acceptable clinical laboratory test screen determine Amgen investigator ; Subject must adequate renal function ( define CrCl &gt; 80 mL/min use Cockcroft Gault equation ) . Subject history evidence clinically significant disorder , condition disease ( include limit cardiopulmonary , oncologic , immunologic , autoimmune , collagen vascular , renal , metabolic , hematologic psychiatric ) , , opinion Investigator consultation Amgen physician , would pose risk subject safety interfere study evaluation , procedures completion ; Subject evidence active suspect bacterial , viral , fungal parasitic infection within past 30 day prior randomization ( eg , common cold , viral syndrome , flulike symptom ) . Subject , opinion investigator , high risk parasitic disease also exclude ; Subject know positive tuberculin skin test ( treated appropriate chemoprophylaxis ) recent ( within six month randomization ) exposure individual active tuberculosis ; Subject history malignancy type , situ cervical cancer surgically excise nonmelanomatous skin cancer within five year randomization study ; Subject know type I/II diabetes ; Subject use nonprescription drug within 14 day prior randomization entire duration study . All herbal supplement , vitamin , nutritional supplement take within last 30 day prior dose Day 1 ( continue use , appropriate ) , must review approve PI Amgen Medical Monitor ; Subject use systemic cytotoxic systemic immunosuppressive medication ( corticosteroid ) within 6 month prior randomization entire duration study ; subject use corticosteroid , topical cytotoxic topical immunosuppressive medication within 30 day five halflives ( whichever longer ) prior randomization entire duration study ; Subject previously receive therapeutic monoclonal antibody ; Subject previously receive investigational drug ( currently use investigational device ) within 30 day five halflives ( whichever longer ) prior randomization ; Subject test positive drug and/or alcohol use screen randomization , subject consume alcohol within 48 hour prior study visit include screening , subject alcohol intake &gt; 2 drinks/day average study ( one drink equivalent 12 ounce regular beer , 8 9 ounce malt liquor , 5 ounce wine 1.5 ounce 80 proof distil spirit ) ; Female subject pregnant lactating ; female subject childbearing potential ; Subject donate blood ( include blood product ) experience loss blood ≥ 500 mL within two month study screen ; Subject positive human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen , hepatitis C antibody ; Subject regularly use nicotine tobacco containing product ( include limit : snuff , chew tobacco , cigar , cigarette , pipe , nicotine patch ) six month randomization study ; Subject condition might reduce chance obtain data ( eg , know poor compliance ) require protocol might compromise ability give truly informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>